SK Biopharm Reports Operating Loss of 239.8 Billion KRW, Down 202% Year-on-Year

[Asia Economy Reporter Junho Hwang] SK Biopharm announced on the 8th that it recorded an operating loss of 239.8 billion KRW last year, a 202.57% decrease compared to the previous year. SK Biopharm's sales amounted to 25.6 billion KRW, down 79.26% from the same period last year. The company stated, "Sales decreased compared to the previous year due to the reflection of the upfront payment from the 2019 Cenobamate Europe technology export contract," and added, "The increase in selling and administrative expenses following the commercialization of Cenobamate in the US in May last year also had an impact."

This content was produced with the assistance of AI translation services.